The First Occurrence of Angioedema After Discontinuation of Angiotensin-Converting Enzyme Inhibitor
| Autor: | Aleesha Kainat, Noor Ul Ain, Chen Rong Phang, Bhawna Agarwal |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Angioedema
biology business.industry angioedema General Engineering facial angioedema Angiotensin-converting enzyme Pharmacology Discontinuation Allergy/Immunology angiotensin-converting enzyme inhibitors Otolaryngology immune system diseases drug-related side effects and adverse reactions Internal Medicine biology.protein Medicine bradykinin mediated angioedema medicine.symptom skin and connective tissue diseases business |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| DOI: | 10.7759/cureus.19553 |
| Popis: | Angioedema is one of the dreaded side effects of angiotensin-converting enzyme (ACE) inhibitors. It has been well established in the literature and the timing of onset is variable from months to years after initiation of therapy. Patients remain at risk of recurrence of angioedema even after discontinuation of the drug if they developed it once while on the drug. While only recurrences of ACE inhibitor-induced angioedema are described in the literature, our patient did not develop angioedema while being on the drug and had the first occurrence of angioedema one month after the medication was discontinued. We argue that since our patient did report an ACE inhibitor-related dry cough, this case emphasizes the strength of the relation between the two common side effects of the ACE inhibitors. This favors that among the risk factors that predispose individuals to develop angioedema, ACE inhibitor-associated cough is a major one. Although the mechanism of ACE inhibitor-related cough is poorly understood, bradykinin seems to be the common culprit mediator for these two side effects. Hence, clinicians need to be aware of this potential threat and be cautioned when they witness an ACE inhibitor-related cough. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|